These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 6105800)
21. Dopaminergic supersensitivity: influence of dopamine agonists and drugs used for the treatment of tardive dyskinesia. Christensen AV; Nielsen IM Adv Biochem Psychopharmacol; 1980; 24():341-9. PubMed ID: 6105784 [No Abstract] [Full Text] [Related]
23. Treatment of tardive dyskinesia. Hollister LE Curr Psychiatr Ther; 1980; 19():89-97. PubMed ID: 6109597 [No Abstract] [Full Text] [Related]
24. Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia. Friedhoff AJ; Rosengarten H; Bonnet K Psychopharmacol Bull; 1978 Oct; 14(4):77-9. PubMed ID: 704769 [No Abstract] [Full Text] [Related]
25. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease. Baron MS; Dalton WB Mov Disord; 2003 Oct; 18(10):1208-9. PubMed ID: 14534933 [No Abstract] [Full Text] [Related]
38. Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series. Bona JR J Clin Psychopharmacol; 2006 Apr; 26(2):215-6. PubMed ID: 16633158 [No Abstract] [Full Text] [Related]
39. [Tardive dyskinesia: etiology, clinical features and therapy]. Furer V; Lichtenberg P; Heresco-Levy U Harefuah; 2001 Mar; 140(3):248-52. PubMed ID: 11303354 [No Abstract] [Full Text] [Related]
40. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia. Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]